Dr. Monty Pal concludes the program by discussing how the treatment landscape for advanced renal cell carcinoma (RCC) may evolve as new clinical evidence emerges.
The FDA granted accelerated approval to RP1 (vusolimogene oderparepvec; Tudriqev), an oncolytic virus therapy, in combination ...
The FDA has cleared an investigational new drug (IND) application for Bria-PROS+, a personalized, off-the-shelf, whole-cell ...
Mark Agulnik, MD, discusses the trend away from surgery and toward targeted treatment of progressive desmoid tumors, and how ...
Phase 3 SENOMAC randomized 2766 patients across five countries to completion ALND vs omission after up to two sentinel-node ...
HR-positive disease accounts for approximately 70% to 80% of breast cancer diagnoses and carries a risk of recurrence that ...
Sagar Lonial, MD, discusses why to take an individualized approach despite the trial's findings supporting discontinuation of lenalidomide at 2 years. Sagar Lonial, MD, of the Winship Cancer Institute ...
City of Hope's Dr Ravi Salgia explains a new national trial using biomarkers to predict immunotherapy success in advanced non ...
FDA tentatively OKs cabozantinib capsules for RCC, HCC and epNET, with dose-conversion guidance, error warning and improved ...
IMMUNO-BIOMAP targets the clinical uncertainty around who benefits from first-line immunotherapy, who experiences early failure, and whether fixed two-year treatment durations are necessary in ...
The FDA issued a complete response letter (CRL) to a new drug application (NDA) for 177 Lu-edotreotide (ITM-11) for the treatment of patients with gastroenteropancreatic neuroendocrine tumors ...
Deep remissions were frequent, with uMRD4 achieved in 86% (blood) and 84% (marrow), rising to 96% in both compartments among CR/CRi responders. Liso-cel CAR T plus ibrutinib delivers deep remissions ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results